Tecan Group AG/€TECN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tecan Group AG
Tecan Group AG is a Swiss company specializing in laboratory instruments and solutions within the life sciences sector. The company offers a range of automated workflow and instrumentation solutions for laboratories involved in diagnostics, bio-pharmaceuticals, and forensics. Founded in 1980 and headquartered in Männedorf, Switzerland, Tecan operates globally, serving clients across various continents. The company's strategic positioning lies in its emphasis on automation and high-throughput systems, which cater to the growing demand for efficiency in laboratory settings. Tecan's products are characterized by their precision and adaptability, allowing for integration into diverse laboratory environments.
- Ticker
- €TECN
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 3,000
- Headquarters
- Männedorf, Switzerland
- Website
- www.tecan.com
Tecan Group AG Metrics
BasicAdvanced
€3.5B
-
-€10.08
1.01
€3.27
0.58%
Price and volume
Market cap
€3.5B
Beta
1.01
52-week high
€271.20
52-week low
€121.40
Average daily volume
79K
Dividend rate
€3.27
Financial strength
Current ratio
2.316
Quick ratio
1.495
Long term debt to equity
0.182
Total debt to equity
0.192
Interest coverage (TTM)
16.20%
Profitability
EBITDA (TTM)
82.415
Gross margin (TTM)
34.06%
Net profit margin (TTM)
-13.36%
Operating margin (TTM)
4.88%
Effective tax rate (TTM)
-7.05%
Revenue per employee (TTM)
€314,200
Management effectiveness
Return on assets (TTM)
1.48%
Return on equity (TTM)
-9.69%
Valuation
Price to revenue (TTM)
3.744
Price to book
2.87
Price to tangible book (TTM)
11.13
Price to free cash flow (TTM)
78.82
Free cash flow yield (TTM)
1.27%
Free cash flow per share (TTM)
3.583
Dividend yield (TTM)
1.16%
Forward dividend yield
0.58%
Growth
Revenue change (TTM)
-3.98%
Earnings per share change (TTM)
-287.88%
3-year revenue growth (CAGR)
-7.55%
10-year revenue growth (CAGR)
6.23%
3-year earnings per share growth (CAGR)
3.12%
10-year earnings per share growth (CAGR)
7.01%
3-year dividend per share growth (CAGR)
1.14%
10-year dividend per share growth (CAGR)
5.54%
Bulls say / Bears say
Q3 sales growth accelerated to 6.9% in local currencies, prompting Tecan to raise its 2026 sales outlook to low-to-mid single-digit growth and its adjusted EBITDA margin range to 16.5%–16.8%. (GlobeNewswire)
Both segments had first-half book-to-bill ratios above one, while recurring services, consumables and reagents rose to 64.4% of Life Sciences sales. That mix can help sustain revenue between instrument purchases. (Tecan)
Tecan has added agentic AI features to its Introspect lab analytics platform with NVIDIA technology, aiming to help labs spot problems and improve productivity. If customers adopt the tools, they could strengthen Tecan’s role in automated laboratories. (Tecan)
Demand from academia and government remained weak, with sales declining in the first half. Continued weakness in this customer group could hold back growth even as biopharma and diagnostics improve. (Tecan)
First-half operating cash flow fell to CHF 17 million from CHF 60 million a year earlier, and cash conversion dropped to 36.5%. Weak cash generation leaves less room for investment or shareholder returns if it persists. (Tecan)
Foreign exchange and tariffs cut first-half adjusted EBITDA margin by a combined 170 basis points, and reported sales fell 2.7% in Swiss francs despite local-currency growth. Further currency or tariff pressure could obscure operating progress and weigh on reported results. (Tecan)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.